Medical NewsGerman Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Cytotoxics (anthracycline antibiotics). |
| Generic Name : | Doxorubicin |
| Drug description : | Sterile, translucent, red suspension in 10mL or 25mL vials. |
| Presentation : | Infusion, doxorubicin hydrochloride (in pegylated liposomes) 2mg per mL. |
| Indications : | Advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 CD lymphocytes/mm3) and extensive mucocutaneous or 4 visceral disease. Caelyx may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline). |
| Adult Dosage : | Caelyx should be administered Caelyx should be administered only under the supervision of a qualified oncologist specialised in the administration of cytotoxic agents. Caelyx exhibits unique pharmacokinetic properties and must not be used interchangeably with other formulations of doxorubicin hydrochloride. Refer to Summary of Product Characteristics. |
| Child Dosage : | Under 18 years, not recommended. |
| Contra Indications : | History of hypersensitivity reactions to components of Caelyx or to doxorubicin. Pregnancy and lactation. Should not be used to treat AIDS Kaposi's sarcoma that may be effectively treated with local therapy or systemic alfa- interferon. |
| Special Precautions : | Cardiac risk, myelosuppression: see Summary of Product Characteristics. Diabetic patients: it should be noted that each vial of Caelyx contains sucrose and is administered in 5% (50mg/mL) glucose intravenous infusion. |
| Interactions : | Caution must be exercised when giving any other cytotoxic agents, especially myelotoxic agents, at the same time. |
| Adverse Reactions : | Leucopenia, thrombocytopenia, anaemia. Refer to Summary of Product Characteristics. |
| Manufacturer : | Schering-Plough |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org